Beone Medicines Ltd. Class A — Fact Sheet (May 2025)

2 slides from Beone Medicines Ltd. Class A's fact sheet, May 2025

Slide 1: BeOne Medicines Corporate Overview
BeOne Medicines Corporate Overview BeOne is a global oncology company that is focused Our two foundational medicines, BTK inhibitor BRUKINSA® (zanubrutinib) and PD-1 inhibitor TEVIMBRA® (tislelizumab), demonstrate the strength on uniting the worldwide community against cancer of our science and our
Slide 2: Facts at a Glance
Facts at a Glance 11k+ $3.8B 1.7M+ 40+ Colleagues globally 2024 total revenue* Patients treated Assets in clinical in over 4 0 offices with our and commercial on 6 continents medicines stages 1.1k+ 3.7k In-house manufacturing 40+ Oncology Clinical development including diversified Phase 3 or potenti